Claims for Patent: 4,533,549

Summary for Patent: 4,533,549

Title:	Antithrombotic agent
Abstract:	The object of the invention is to provide a new antithrombotic agent. Coagulation of blood acts through a cascade of stages, the mechanisms and interaction of which have not been fully clarified. The present invention provides a derivative of heparin which can be administered orally, topically, or parenterally to antagonize the effect of factor Xa to a greater extent than commercial porcine heparin. In addition, the derivative has insignificant USP anticoagulant and platelet aggregating activities. The heparin derivative according to the invention, has a molecular weight of from about 2,500 to about 4,000 daltons, gives a positive metachromatic test for sulfated polysaccharides. Preferably, when isolated as the sodium salt, the derivative contains by elemental analysis about 26.2% carbon, 4.33% hydrogen, 1.98% nitrogen, 7.1% sulfur, and 9.8% sodium, the molar ratio C:N:S:Na being about 10:1.5:2:4.
Inventor(s):	Lasker; Sigmund E. (Roosevelt Island, New York, NY)
Assignee:
Application Number:	06/580,761
Patent Claims:	1. An antithrombotic agent derived from heparin having an anticoagulant activity of less than 20 USP XVIII units and insignificant platelet aggregating activity, and an anti-activated coagulation factor Xa activity of from about 150 to about 190 units/mg, said agent being a pharmacologically acceptable salt of a mucopolysaccharide soluble in water, insoluble in acetone and ethanol, containing glucosamine, glucuronic acid and iduronic acid, having a weight average molecular weight of from about 2,500 to about 4,000 daltons, giving a positive metachromatic test for sulfated polysaccharides. 2. An antithrombotic agent according to claim 1 having an anticoagulant activity of about 13 USP XVIII units. 3. An antithrombotic agent according to claim 1 which is derived from a member selected from the group consisting of porcine heparin, bovine heparin, heparin residues and marine heparinoids. 4. An antithrombotic agent according to claim 3 which is derived from porcine heparin. 5. An antithrombotic agent according to claim 1 wherein the weight average molecular weight is about 3,500 daltons. 6. An antithrombotic agent according to claim 1 which, when isolated as a sodium salt, contains by elemental analysis about 26.2% carbon, 4.33% hydrogen, 1.98% nitrogen, 7.1% sulfur, and 9.8% sodium, the molar ratio C:N:S:Na being about 10:1.5:2:4. 7. A dosage form of the antithrombotic agent of claim 1 comprising from about 100 to about 500 mg. of said agent in a pharmaceutically acceptable carrier. 8. A dosage form according to claim 7 wherein the carrier comprises a solid, water-soluble excipient. 9. A dosage form according to claim 7 wherein the carrier comprises sterile water.

Details for Patent 4,533,549

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2002-08-06